Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836755 | 0.89 | KMT2A (0.38) | CYP2D6KMT2ATSHRHSD17B10CA1 | |
| SCHEMBL23038453 | 0.85 | CTSS (0.38) | CYP2D6KMT2ACA1CA2CA7 | |
| SCHEMBL30455998 | 0.84 | CTSS (0.35) | CYP2D6KMT2ACA1CA2CA7 | |
| SCHEMBL25836705 | 0.78 | DGAT2 (0.44) | KMT2ATSHRHSD17B10CA1CA2 | |
| SCHEMBL23357725 | 0.75 | CTSS (0.37) | KMT2AMEN1ATMTRPA1CTSK | |
| SCHEMBL25836736 | 0.74 | CA1 (0.42) | CA1CA2CA7ALDH1A1L3MBTL1 | |
| SCHEMBL25397406 | 0.74 | KDM4E (0.34) | CYP2D6CA1CA7ALDH1A1ATM | |
| SCHEMBL28503393 | 0.74 | CTSK (0.34) | HSD17B10CA1CA2CA7ATM | |
| SCHEMBL3586455 | 0.74 | ALPL (0.47) | KMT2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3122071 | 0.73 | ALPL (0.46) | KMT2AALDH1A1L3MBTL1FPR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | CYP2D6 241/4885KMT2A 2610/4885TSHR 4401/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | CYP2D6 241/4885KMT2A 2610/4885TSHR 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.